Turn Therapeutics Atopic Dermatitis Candidate Reduces Disease Severity by 57% In-Vivo
June 20 2024 - 12:57PM
Business Wire
In-vivo study shows 57% reduction in ISGA score vs 10% placebo
in seven days
In a widely cited in-vivo model of atopic dermatitis, Turn
Therapeutics' atopic dermatitis candidate showed a dramatic
reduction in disease severity versus placebo.
At the conclusion of a seven-day disease induction, the mean
severity score across all groups was 3.3 on the ISGA scale, an
atopic dermatitis disease assessment that ranges from 0, or
completely clear, to 4, or severe eczema.
After seven days of treatment, Turn Therapeutics' candidate
reduced ISGA score to 1.44, a 57% reduction, versus 3.0 for
placebo, or a 10% reduction. The formula underlying Turn
Therapeutics' candidate has a history of safe use in humans and a
confirmed lack of cytotoxicity or sensitization in existing
clearances from the U.S. Food and Drug Administration.
"People with atopic dermatitis are in dramatic need of safe and
effective non-steroid, non-injectable treatment options," said
Bradley Burnam, founder and CEO of Turn Therapeutics. "With a
reduction of 1.89 points in the ISGA scale after only seven days,
as well as confirmed inflammatory markers after induction, we
expect to uncover notable immunological activity of our atopic
dermatitis candidate."
Study results and further information can be found at
turntherapeutics.com.
About Turn Therapeutics
Turn Therapeutics is a pharmaceutical and medical device company
focused on advanced wound and dermatologic care. Turn's technology
targets broad indications with few safe or effective options, such
as moderate to severe eczema and onychomycosis. Leveraging the
guidance and data produced by medical experts, Turn's innovative
flagship formula continues to suggest remarkable efficacy for a
variety of indications. Visit turntherapeutics.com.
The statements contained herein may include prospects,
statements of future expectations, and other forward-looking
statements that are based on management's current views and
assumptions and involve known and unknown risks and uncertainties.
Actual results, performance, or events may differ materially from
those expressed or implied in such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240620540511/en/
Maggie Servais maggie@keybridge.biz 202-516-6584